Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more
Scancell Hldgs Plc (SCLP) - Total Liabilities
Latest total liabilities as of October 2025: GBX23.75 Million GBX
Based on the latest financial reports, Scancell Hldgs Plc (SCLP) has total liabilities worth GBX23.75 Million GBX as of October 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Scancell Hldgs Plc - Total Liabilities Trend (2005–2025)
This chart illustrates how Scancell Hldgs Plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Scancell Hldgs Plc Competitors by Total Liabilities
The table below lists competitors of Scancell Hldgs Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EUROBOND
NSE:EUROBOND
|
India | ₹1.96 Billion |
|
GREAT WALL MOTOR-H-
BE:GRV
|
Germany | €132.76 Billion |
|
CPTL & COUNT PROP
BE:C20
|
Germany | €1.74 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Scancell Hldgs Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scancell Hldgs Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scancell Hldgs Plc (2005–2025)
The table below shows the annual total liabilities of Scancell Hldgs Plc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | GBX26.93 Million | -0.58% |
| 2024-04-30 | GBX27.08 Million | -25.81% |
| 2023-04-30 | GBX36.50 Million | +23.43% |
| 2022-04-30 | GBX29.57 Million | +2427.61% |
| 2021-04-30 | GBX1.17 Million | -2.94% |
| 2020-04-30 | GBX1.21 Million | 0.00% |
| 2019-04-30 | GBX1.21 Million | +73.17% |
| 2018-04-30 | GBX696.09K | +30.87% |
| 2017-04-30 | GBX531.88K | -7.60% |
| 2016-04-30 | GBX575.65K | -4.68% |
| 2015-04-30 | GBX603.91K | +12.34% |
| 2014-04-30 | GBX537.59K | +70.60% |
| 2013-04-30 | GBX315.11K | +10.81% |
| 2012-04-30 | GBX284.38K | +133.10% |
| 2011-04-30 | GBX122.00K | -73.01% |
| 2010-04-30 | GBX452.00K | +170.66% |
| 2009-04-30 | GBX167.00K | +89.02% |
| 2008-04-30 | GBX88.35K | -57.15% |
| 2007-04-30 | GBX206.21K | +415.52% |
| 2006-04-30 | GBX40.00K | -31.03% |
| 2005-08-31 | GBX58.00K | -- |